For example, one study found that 44% of 380 patients had extracapsular extensions, indicating that PSAD is an independent predictor that distinguishes HR-PCa from PCa and predicts PSA-free survival.[25] Further, the 5-year PSA-free survival rates are 82.9% for patients with PSAD <0.468 ng·ml-2 and 50.7% for those with PSAD >0.468 ng·ml -2 (P <0.001). Here, KLK3 is linked to posterior cortical atrophy.